Basilea announces change in its management structure
Ronald Scott was appointed Chief Financial Officer at the company's inception. In addition to finance, business development, investor relations and public relations, he now assumes responsibility for commercial activities, manufacturing and corporate services with the respective departments retaining their heads. He will continue as ad interim Chief Financial Officer. In line with Basilea's strategic focus to bring innovative new drugs to the market, research and development, including Basilea's operations in China, will continue to report directly to Chief Executive Officer, Dr. Anthony Man.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.